Safety and efficacy of different initial doses of lurasidone in the schizophrenia treatment: A multi-center, randomized, open-label study

Table 1 Patient demographic and clinical characteristics at baseline (full analysis set), mean ± SD/n (%)

Characteristic	Lurasidone (40 mg/day), n = 99	Lurasidone (80 mg/day), n = 98	Overall, n = 197
Age (years)	35.7 ± 12.13	34.1 ± 11.15	34.9 ± 11.65
Male	37 (37.4)	29 (29.6)	66 (33.5)
Female	62 (62.6)	69 (70.4)	131 (66.5)
Body weight (kg)	64.98 ± 18.50	61.04 ± 12.21	63.02 ± 15.77
BMI (kg/m2)	23.89 ± 5.87	22.97 ± 4.30	23.43 ± 5.16
PANSS total score	86.5 ± 11.93	87.7 ± 12.03	87.1 ± 11.96
CGI-S score
4 points	12 (12.1)	18 (18.4)	30 (15.2)
5 points	60 (60.6)	61 (62.2)	121 (61.4)
6 points	26 (26.3)	16 (16.3)	42 (21.3)
7 points	1 (1.0)	3 (3.1)	4 (2.0)
CDSS score	3.0 ± 3.98	2.5 ± 3.91	2.8 ± 3.94
AIMS total score	0.1 ± 0.38	0.1 ± 1.11	0.1 ± 0.83
BARS score
0 points	85 (85.9)	90 (91.8)	175 (88.8)
1 point	4 (4.0)	2 (2.0)	6 (3.0)
2 points	7 (7.1)	4 (4.1)	11 (5.6)
3 points	1 (1.0)	2 (2.0)	3 (1.5)
4 points	2 (2.0)	0 (0)	2 (1.0)
SAS total score	0.4 ± 1.61	0.3 ± 0.99	0.3 ± 1.34
Prior antipsychotic medication	71 (71.7)	77 (78.6)	148 (75.1)
Number of episodes	2.7 ± 5.04	2.8 ± 3.52	2.8 ± 4.34

BMI: Body mass index; PANSS: Positive and Negative Syndrome Scale; CGI-S: Clinical Global Impression Scale-Severity; CDSS: Calgary Depression Scale for Schizophrenia; AIMS: Abnormal Involuntary Movement Scale; BARS: Barnes Akathisia Rating Scale; SAS: Self-Rating Anxiety Scale.